MITSUBISHI TANABE PHARMA AMERICA: Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). Read More »